Meet Inspiring Speakers and Experts at our 3000+ Global Conference Series Events with over 1000+ Conferences, 1000+ Symposiums
and 1000+ Workshops on Medical, Pharma, Engineering, Science, Technology and Business.

Explore and learn more about Conference Series : World's leading Event Organizer

Back

Gita Chawla


Gita Chawla

Hamdard University, India

Biography

A novel series of 1-{[3-(furan-2-yl)-5-substituted phenyl-4,5-dihydro-1,2-oxazol-4-yl]methyl}-4-methyl piperazine, compounds 3a–l have been synthesized. The synthetic work was carried out beginning from 2-acetylfuran through Claisen Schmidt condensation with different types of aromatic aldehyde, affording 1-(furan-2-yl)-3-substituted phenyl prop-2-en-1-ones which on cyclization with hydroxylamine hydrochloride resulted in 3-(furan-2-yl)-5-substitutedphenyl-4,5-dihydro-1,2-oxazole formation. The isoxazolines were subjected to Mannich’s reaction in the presence of N-methyl piperazine to produce the desired products. The chemical structures of the compounds were proved by IR, 1HNMR, 13CNMR and Mass spectrometric data. The antidepressant activity of the compounds was investigated by Porsolt’s behavioral despair (forced swimming) test on Albino mice. Moreover, the antianxiety activity of the newly synthesized compounds was investigated by the plus maze method. Compounds 3a and 3k showed the duration of immobility times of 152.00(s) and 152.33(s) respectively at 10 mg/kg dose level when compared to the standard drug imipramine (149.67s). Compounds 3a and 3k also showed significant antianxiety activity. A computational study for the prediction of ADME properties of the compounds was performed. It was encouraging to note that none of the compounds violated any Lipinski’s parameter. Lipophilicity data also suggested that compounds are lipophilic enough to cross blood brain barrier. The molecular modelling studies also predicted good binding interactions of most active molecules with MAO-A. 

Abstract

Abstract : Design, synthesis and pharmacological evaluation of some novel derivatives of 1-{[3-(furan-2-yl)-5-phenyl-4,5-dihydro-1,2-oxazol-4-yl]methyl}-4-methyl piperazine